• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » ESC 2013: Pacemakers set life expectancy back to normal, researchers say

ESC 2013: Pacemakers set life expectancy back to normal, researchers say

September 6, 2013 By Ingrid Mezo

Dutch study shows pacemakers for slow heart rhythm restore life expectancy

A slow heart rhythm puts patients at risk of early death, but a cardiac implant may help reset those odds, according to a Dutch study presented this week at the European Society of Cardiology Congress in Amsterdam.

A study of pacemakers in 23 Dutch hospitals found that devices implanted to treat slow heart rhythm helped restore normal life expectancy.

Outcomes depended on whether patients also had cardiovascular disease, according to Dr. Erik Udo, who presented the results at the ESC conference. The study helps shed light on an old mystery, Udo added.

"Previous studies describing the survival of pacemaker patients used data that is more than 20 years old and cannot be used anymore for patient counseling and benchmarking," Dr. Udo said in prepared remarks. "There have been considerable changes in pacemaker technology and in the profile of pacemaker patients and a new reference point of prognosis in modern day cardiac pacing was needed."

The Dutch FollowPace study spanned multiple centers and included 1,517 patients who received their 1st pacemaker for slow or irregular heart rhythm, known as bradycardia, between 2003 and 2007, following them for an average of 5.8 years.

Participants had survival rates of 93%, 81%, 69% and 61% after 1, 3, 5 and 7 years, respectively. Those without cardiovascular diseases such as heart failure or coronary artery disease at the time of pacemaker implantation had similar survival rates to general population controls, matched by age and sex, the study found.

Dr. Udo urged doctors to pay more attention to the detection and treatment of cardiovascular problems beyond rhythm deficiencies in patients with pacemakers in order to improve their prognoses.

"The FollowPace study provides detailed documentation of current standard pacemaker care in a large representative sample of western pacemaker clinics," Dr. Udo concluded. "The results can therefore be considered a new benchmark of life expectancy of patients treated with today’s cardiac pacing."

Filed Under: News Well, Research & Development Tagged With: Cardiac Rhythm Management, Clinical Trials, Conference coverage, European Society of Cardiology, European Society of Cardiology Congress

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy